What is the recommended dosing for Wellbutrin (bupropion) in a patient who is a CYP2D6 intermediate metabolizer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Wellbutrin Dosing for CYP2D6 Intermediate Metabolizers

For CYP2D6 intermediate metabolizers taking Wellbutrin (bupropion), use standard dosing protocols without adjustment, as bupropion is primarily metabolized by CYP2B6, not CYP2D6. 1, 2

Key Pharmacokinetic Principle

  • Bupropion is metabolized primarily by CYP2B6 to form its active metabolite hydroxybupropion, not by CYP2D6 2, 3
  • CYP2D6 metabolizer status does not affect bupropion clearance or exposure 2
  • The CYP2D6 intermediate metabolizer genotype is therefore not relevant for bupropion dose adjustments 2, 3

Standard Dosing Recommendations

For Major Depressive Disorder:

  • Start with 150 mg once daily for 3 days, then increase to 150 mg twice daily (300 mg total daily) of the SR formulation 1
  • For XL formulation: start 150 mg once daily, increase to 300 mg once daily as maintenance 1
  • Maximum dose: 400 mg/day for SR; 450 mg/day for XL 1

For Smoking Cessation:

  • 150 mg twice daily (300 mg total) of SR formulation 1
  • Begin dosing 1-2 weeks before target quit date 1
  • Treatment duration: 7-12 weeks 1

Critical Clinical Consideration: Bupropion as CYP2D6 Inhibitor

The important interaction runs in the opposite direction: bupropion is a potent CYP2D6 inhibitor, not a CYP2D6 substrate 3, 4. This means:

  • Bupropion inhibits CYP2D6 in a dose-dependent manner 4
  • At 150 mg/day: 19% of patients are phenoconverted to CYP2D6 poor metabolizers 4
  • At ≥300 mg/day: 50% of patients are phenoconverted to CYP2D6 poor metabolizers 4

Practical Implications:

  • If the patient is taking other medications metabolized by CYP2D6 (e.g., venlafaxine, tricyclic antidepressants, metoprolol, codeine), those drugs may require dose reduction 3, 4
  • The patient's baseline CYP2D6 intermediate metabolizer status makes them more vulnerable to complete CYP2D6 inhibition when bupropion is added 4
  • Consider therapeutic drug monitoring for CYP2D6 substrate medications during bupropion comedication 4

Dose Adjustments That Actually Matter

Adjust bupropion doses for these conditions only:

  • Hepatic impairment (moderate to severe): maximum 150 mg daily total 1
  • Renal impairment (moderate to severe, GFR <90 mL/min): reduce total daily dose by 50% 1
  • Older adults: start with 37.5 mg every morning, increase by 37.5 mg every 3 days as tolerated, maximum 300 mg/day 1

Safety Monitoring

  • Seizure risk: maximum dose should not exceed 450 mg/day; contraindicated in seizure disorders 1
  • Blood pressure monitoring: bupropion should be avoided in uncontrolled hypertension 1
  • Timing of second dose: administer before 3 PM to minimize insomnia risk 1
  • Neuropsychiatric effects: monitor especially in patients <24 years old 1

References

Guideline

Bupropion Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Bupropion: pharmacology and therapeutic applications.

Expert review of neurotherapeutics, 2006

Research

Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression.

Journal of clinical psychopharmacology, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.